Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer
Candel Therapeutics (CADL) has appointed Mark Sims as its new Chief Commercial Officer, effective July 6, 2026. With over two decades of experience in oncology commercial strategy and leadership roles at major pharmaceutical companies like AstraZeneca and Merck & Co., Sims will lead the company's efforts for a potential product launch in early 2027.